Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 162

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Small cell lung cancer

Not yet recruiting

Study on the Safety and Effectiveness of AL8326 for Patients with Small Cell Lung Cancer Needing Second-Line Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AL8326
  • Sponsor:Advenchen Pharmaceuticals LLC

Pancreatic carcinoma

Not yet recruiting

Study on the Safety and Tolerability of CEB-01 in Patients with Pancreatic Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:7-Ethyl-10-Hydroxycamptothecin
  • Sponsor:Cebiotex S.L.

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Colorectal cancer metastatic

Not yet recruiting

Study of LB-100 and Azenosertib for Patients with Metastatic Colorectal Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Hormone receptor positive breast cancer

Not yet recruiting

Study Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Academisch Ziekenhuis Maastricht

Breast cancer female

Not yet recruiting

Study on the Use of Iomeprol in Contrast Enhanced Mammography for Identifying Breast Cancer in Patients with BIRADS 4 or 5 Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Iomeprol
  • Sponsor:Azienda Ospedaliero-Universitaria Policlinico Umberto I

Renal cell carcinoma

Not yet recruiting

Study of Axitinib and Avelumab for Patients with Localized Renal Cell Carcinoma at Moderate to High Risk of Recurrence

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Malignant peritoneal neoplasm+2

Not yet recruiting

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Agencja Badań Medycznych

Bladder cancer stage 0 with cancer in situ+1

Not yet recruiting

Study on the Safety and Effectiveness of TARA-002 for Adults with High-Grade Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Streptococcus Pyogenes, Group A, Type 3, Strain Su, Inactivated
  • Sponsor:Protara Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.